CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
of three drugs called lenalidomide, subcutaneous (injection under the skin) bortezomib, and dexamethasone (RVD) as a possible treatment for multiple...
Phase 2
Morristown, New Jersey, United States and 7 other locations
multicenter, dose-escalation study of STI-6129 administered intravenously once in a 4-week cycle in subjects with relapsed or refractory multiple...
Phase 1, Phase 2
New York, New York, United States and 2 other locations
in combination with dexamethasone in subjects with newly diagnosed multiple myeloma followed by treatment with a combination of dru...
Phase 2
New York, New York, United States
and safety of bb2121 in participants with relapsed and refractory multiple myeloma (RRMM) (Cohort 1), in participants with RRMM who ...
Phase 2
New York, New York, United States and 25 other locations
(DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple...
Phase 3
New York, New York, United States and 145 other locations
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.
Phase 1, Phase 2
Hackensack, New Jersey, United States and 48 other locations
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple...
Phase 1
New York, New York, United States and 9 other locations
of these combinations in participants with relapsed or refractory multiple myeloma. The study will consist of 3 distinct parts: Par ...
Phase 2
New York, New York, United States and 40 other locations
The purpose of this research study is to evaluate a treatment regimen called IRD which will be given to participants after their stem cell transplant...
Phase 2
New York, New York, United States and 9 other locations
versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...
Phase 3
New York, New York, United States and 59 other locations
Clinical trials
Research sites
Resources
Legal